Asymmetric Learning - Pharmaceutical Innovation
Mike ReaInnovations in Pharmaceutical Innovation A blog/ part-work from Mike Rea, exploring pharmaceutical innovation in general, and more specifically the approach to using the learning process for competitive advantage
| Platform |  | Pricing | Only free issues | Publishes | Twice weekly |
|---|---|---|---|---|---|
| Issues | 340 | Founded | 6 years ago | Last Issue | 7 days ago |
| Active | |||||
Read this Newsletter
asymmetriclearning.substack.comLatest Issues
Plan the Questions, Not the Assets
In High? Long? Both?, I suggested moving the unit of analysis once. Among finished chronic-disease lifecycles, lifetime revenue is mostly peak. Effective duration - lifetime sales divided by the best single year - sits around twelve peak-ye...
What would change the end for ivonescimab in the West?
On 30 May 2024 Akeso said ivonescimab had beaten Keytruda head-to-head in a Chinese Phase III in PD-L1-positive lung cancer. This month in Seoul the survival data arrived: median OS of 30.8 months against 22.6, hazard ratio 0.73, at an inte...
Asymmetry, measured in milliseconds (five years on)
On 30 May 2024 Akeso said ivonescimab had beaten Keytruda head-to-head in a Chinese Phase III in PD-L1-positive lung cancer. When the full data landed at WCLC that September, median PFS was 11.1 months against 5.8, hazard ratio 0.51. Everyo...
High? Long? Both?
A finished blockbuster earns about twelve times its best year. The tirzepatide argument is whether it gets the twelve.
Humira’s best year, in today’s money, was about $26 billion. Tirzepatide’s run-rate in the first half of 2026 is roughly...
Opportunity-seeking behaviour, five years on
A molecule entering Phase I today has, on the latest ten-year Citeline data, a 6.7% chance of approval. Phase II remains the wall: 28% of programmes get through it. And the Phase I transition rate, which sat above 75% in the 2006-08 cohorts...
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Asymmetric Learning.
| Subscribers | Engagement | 73 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Was CEO, IDEA Pharma, now CEO, Then, If… Pharmaceutical innovation geek. Author: Pharmaceutical Positioning. My record label: Medical Records. Large, Geordie, dog fan, street-foodie
Social
Frequently Asked Questions
How can I access the email archive for Asymmetric Learning?
You can find recent issues that have been published by Asymmetric Learning on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Asymmetric Learning have?
To see how many people subscribe to Asymmetric Learning, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Asymmetric Learning?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Asymmetric Learning as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Asymmetric Learning?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Asymmetric Learning using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Asymmetric Learning?
Scroll up to where it says Related Newsletters to see other publications like Asymmetric Learning. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Asymmetric Learning?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.